Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorLewis, Joseph M.
dc.contributor.authorSloan, Derek James
dc.date.accessioned2016-04-20T15:16:56Z
dc.date.available2016-04-20T15:16:56Z
dc.date.issued2015-05-13
dc.identifier.citationLewis , J M & Sloan , D J 2015 , ' The role of delamanid in the treatment of drug-resistant tuberculosis ' , Therapeutics and Clinical Risk Management , vol. 11 , pp. 779-791 . https://doi.org/10.2147/TCRM.S71076en
dc.identifier.issn1176-6336
dc.identifier.otherPURE: 241921046
dc.identifier.otherPURE UUID: 14bb6867-58b1-42e4-97bc-8c9bf0210ef6
dc.identifier.otherScopus: 84930204442
dc.identifier.urihttps://hdl.handle.net/10023/8654
dc.description.abstractTuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.
dc.format.extent13
dc.language.isoeng
dc.relation.ispartofTherapeutics and Clinical Risk Managementen
dc.rights© 2015 Lewis and Sloan. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.en
dc.subjectDelamaniden
dc.subjectOPC-67683en
dc.subjectTuberculosisen
dc.subjectDrug resistanceen
dc.subjectMDR-TBen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectRS Pharmacy and materia medicaen
dc.subjectPharmacology (medical)en
dc.subjectMedicine(all)en
dc.subjectPharmacology, Toxicology and Pharmaceutics(all)en
dc.subjectSafety Researchen
dc.subjectChemical Health and Safetyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRA0421en
dc.subject.lccRSen
dc.titleThe role of delamanid in the treatment of drug-resistant tuberculosisen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doihttps://doi.org/10.2147/TCRM.S71076
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record